Cargando…
Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis
BACKGROUND: Metastatic breast cancer (MBC) patients with low expression of human epidermal growth factor 2 (HER2) have been proven to benefit from HER2 targeted therapy. We aimed to determine how HER2-low status affected survival and metastatic risk as well as how it affected pathological complete r...
Autores principales: | Dai, Lanyi, Huang, Qiyuan, Guo, Rong, Zhu, Keying, Tang, Yiyin, Chen, Dedian, Huang, Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676074/ https://www.ncbi.nlm.nih.gov/pubmed/38023289 http://dx.doi.org/10.1177/11795549231202463 |
Ejemplares similares
-
Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023) -
Comparison of Sentinel Lymph Node Biopsy by Blue Dye Conjunction With Indocyanine Green or Radioisotope in Early-Stage Breast Cancer: A Prospective Single-Center Observational Study
por: Wang, Yanmei, et al.
Publicado: (2023) -
Cancer nutrition and rehabilitation—its time has come!
por: Chasen, M.R., et al.
Publicado: (2008) -
Healing and survivorship: what makes a difference?
por: Braude, H.D., et al.
Publicado: (2008) -
Workplace support for employees with cancer
por: Nowrouzi, B., et al.
Publicado: (2009)